Project Grant F31CA210607

This Project Grant award for $627,939 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a collaborative effort to develop and validate a cost-effective, scalable diagnostic solution for characterizing pediatric cancers in low- and middle-income countries (LMIC) using nanopore sequencing technology. The primary awardee, the University of North Carolina at Chapel Hill, will work with partners at St. Jude Children's Research...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize germline genetic variants and perform functional validation in a zebrafish model of high-risk pediatric acute myeloid leukemia (AML). The $101,948 award will also fund work to investigate germline regulatory, splicing, and structural variants, as well as viral genomic integrations, as potential catalysts of leukemia risk. The research aims to...

This $695,464 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to map the causal variants and mechanisms underlying genetic predisposition to childhood B-cell acute lymphoblastic leukemia (B-ALL). The award to Boston Children's Hospital will integrate results from a multi-ancestry genome-wide association study (GWAS) with single-cell epigenomic data to pinpoint causal variants at known B-ALL risk loci. The team will then use...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is focused on developing a "next-generation" precision adoptive T cell therapy approach to treat pediatric high-grade gliomas. The $474,656 award will fund research to evaluate the safety, efficacy, and immunological effects of this therapy in preclinical models, determine the capacity to isolate and expand antigen-specific T cells from pediatric patients, and conduct a Phase 1...

This federal Project Grant award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) provides $699,080 to the Ann & Robert H. Lurie Children's Hospital of Chicago to implement Optical Genome Mapping (OGM) as a first-line diagnostic approach for pediatric brain tumors. The project aims to utilize OGM technology to rapidly identify clinically significant structural variants in pediatric brain tumors that may guide treatment plans for...

The Department of Defense's Defense Health Agency awarded a $3,188,604 Project Grant titled "USE OF HIGH-THROUGHPUT SEQUENCING OF THE IMMUNOGLOBULIN LOCI FOR REFINED RISK STRATIFICATION IN PEDIATRIC B-ALL" to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. This grant, funded through the Military Medical Research and Development (CFDA 12.420) program, supports biomedical research related to military medicine, with a focus on cancer, neurological...

This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...

This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $562,869 to Children's Hospital Los Angeles to investigate the role of chromosome 17q gain in the malignancy of neuroblastoma, a common pediatric solid tumor. The research project aims to: 1) compare the tumorigenic potential of 17q gain and MYCN overexpression in cells that give rise to sympathoadrenal cells, the cell of origin for neuroblastoma; 2) determine genes...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $788,589 to Children's Hospital Los Angeles to conduct research on the cooperation of FOXR2 and ETS transcription factors in diffuse midline gliomas, a type of devastating childhood brain tumor. The award period runs from August 15, 2024 to July 31, 2029. The research aims to 1) test the hypothesis that ETS transcription factors are required for FOXR2-mediated oncogenesis, and 2)...

This is a $1,593,000 federal Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant was awarded on September 1, 2023 to The Children's Hospital Corporation, doing business as Boston Children's Hospital, a non-profit pediatric teaching hospital and research center. The funding supports a 3-year research project to "DEFINING THE UNIVERSAL GENOMIC LANGUAGE OF HALLMARKS IN TUMOR...